(Q34027292)

30 July 2017

1 reference

title

Direct thrombin inhibitors as adjuncts to thrombolytic therapy (English)

1 reference

30 July 2017

1 reference

2

H D White

1 reference

30 July 2017

J K French

1

1 reference

30 July 2017

1 September 1999

1 reference

Current cardiology reports

30 July 2017

1 reference

30 July 2017

1

1 reference

30 July 2017

3

1 reference

30 July 2017

184-191

1 reference

https://scigraph.springernature.com/pub.10.1007/s11886-999-0021-0

30 July 2017

0 references

cites work

Prospective evaluation of eligibility for thrombolytic therapy in acute myocardial infarction

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11886-999-0021-0

Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11886-999-0021-0

Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction

21 January 2018

1 reference

12 December 2020

Failure of fixed dose intravenous heparin to suppress increases in thrombin activity after coronary thrombolysis with streptokinase

1 reference

12 December 2020

Long-term prognostic importance of patency of the infarct-related coronary artery after thrombolytic therapy for acute myocardial infarction

1 reference

12 December 2020

Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators

1 reference

12 December 2020

Induction of marked thrombin activity by pharmacologic concentrations of plasminogen activators in nonanticoagulated whole blood

1 reference

12 December 2020

Activation/inactivation of human factor V by plasmin

1 reference

12 December 2020

Randomized factorial trial of high-dose intravenous streptokinase, of oral aspirin and of intravenous heparin in acute myocardial infarction. ISIS (International Studies of Infarct Survival) pilot study

1 reference

12 December 2020

Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators

1 reference

12 December 2020

Recombinant hirudin (lepirudin) for the improvement of thrombolysis with streptokinase in patients with acute myocardial infarction: results of the HIT-4 trial

1 reference

12 December 2020

Role of heparin in coronary thrombolysis

1 reference

12 December 2020

High dose heparin as pretreatment for primary angioplasty in acute myocardial infarction: the Heparin in Early Patency (HEAP) randomized trial.

1 reference

12 December 2020

Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK)

1 reference

12 December 2020

Perspectives on large-scale cardiovascular clinical trials for the new millennium. The Virtual Coordinating Center for Global Collaborative Cardiovascular Research (VIGOUR) Group

1 reference

12 December 2020

A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. Heparin-Aspirin Reperfusion Trial (HART) Investigators

1 reference

12 December 2020

Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors

1 reference

12 December 2020

Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation: a pilot study. Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators

1 reference

12 December 2020

A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction

1 reference

12 December 2020

A Comparison of Recombinant Hirudin with Heparin for the Treatment of Acute Coronary Syndromes

1 reference

12 December 2020

A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial

1 reference

12 December 2020

Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial

1 reference

12 December 2020

Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety

1 reference

12 December 2020

Clinical outcomes of bivalirudin for ischemic heart disease

1 reference

12 December 2020

A randomized trial of intravenous heparin in conjunction with anistreplase (anisoylated plasminogen streptokinase activator complex) in acute myocardial infarction: the Duke University Clinical Cardiology Study (DUCCS) 1

1 reference

12 December 2020

Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial

1 reference

12 December 2020

Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Organisation

1 reference

12 December 2020

Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction

1 reference

12 December 2020

Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin

1 reference

12 December 2020

Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial

1 reference

12 December 2020

Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb Trial. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coron

1 reference

12 December 2020

High dose bolus heparin as initial therapy before primary angioplasty for acute myocardial infarction: results of the Heparin in Early Patency (HEAP) pilot study

1 reference

12 December 2020

10.1007/S11886-999-0021-0

Identifiers

DOI

1 reference

PubMed ID

10980840

Dimensions Publication ID

30 July 2017

0 references

1 reference

PubMed ID

10980840